{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Change from Baseline in other lung function measurements', '(absolute and relative FEV1, AM/PM peak expiratory flow (PEF),', 'FVC, forced expiratory flow (FEF) 25-75%, post-bronchodilator', '% predicted FEV1) at Weeks 2, 4, 8, 12, 24, 36, 52 and other time', 'points assessed.', 'The effect of dupilumab on healthcare resource utilization', 'Change from Baseline at Weeks 2, 4, 8, 12, 24, 36, 52, and other', 'time points assessed, in:', '-', 'Morning/evening asthma symptom score (electronic diary)', '-', 'PRO:', 'Asthma Control Questionnaire-Interviewer Administered', '(ACQ-IA), for children 6 to <12 years old', '-', 'Use of reliever medication', '-', 'Number of nocturnal awakenings due to asthma symptoms', 'requiring the use of reliever medication', 'Change from Baseline at Weeks 12, 24, 36, 52, 64 in:', '-', 'PRO:', 'Paediatric Asthma Quality of Life Questionnaire With', 'Standardised Activities-Interviewer Administered', '(PAQLQ(S) IA) score, for children >7 to <12 years old at', 'randomization.', 'Safety and tolerability', 'Adverse events (AEs)', 'Vital signs (including height, weight)', 'Physical examination', 'Electrocardiogram (ECG)', 'Clinical laboratory tests', 'Systemic drug concentration, anti-drug antibodies and', 'IgG responses to vaccination during drug treatment', 'Serum functional dupilumab concentrations', 'ADA', 'IgG responses to vaccination with any vaccination for tetanus,', 'diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza', 'vaccine during dupilumab treatment (may be analyzed as', 'exploratory endpoint if insufficient power).', 'Biomarkers', 'Change from baseline in fractional exhaled nitric oxide (FeNO) at', 'Week 12.', 'Exploratory endpoints:', 'Change from baseline and blood biomarkers (thymus and activation', 'regulated chemokine [TARC], serum total immunoglobulin E [IgE]).', 'The proportion of patients requiring a permanent step up in', 'background controller medication after 2 or more severe asthma', 'exacerbation events.', 'Property of the Sanofi Group - strictly confidential', 'Page 13', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'The effect of dupilumab on additional PROs:', '-', \"Pediatric Asthma Caregiver's Quality of Life Questionnaire\", '(PACQLQ) score, for caregivers of children 7 years old at', 'randomization', '-', 'Pediatric Rhinoconjunctivitis Quality of Life Questionnaire -', 'Interviewer Administered (PRQLQ-IA) score, in children 6 to', '<12 years old, with history of allergic rhinitis)', 'EuroQol 5 dimension youth questionnaire (EQ-5D-Y) for', 'children', 'Change from Baseline in antigen-specific IgE, antigen-specific', 'immunoglobulin G subtype 4 (lgG4) and', 'ratio of IgE:lgG4', 'Slope of % predicted FEV1', 'Criteria for Asthma Exacerbations during the study:', 'Two types of asthma exacerbation are defined in this study, as outlined', 'below:', '1) A severe exacerbation event during the study is defined as a deterioration', 'of asthma requiring:', 'Use of systemic corticosteroids for >3 days; or', 'Hospitalization or emergency room visit because of asthma,', 'requiring systemic corticosteroids', '2) A LOAC event is defined as any of the following:', '6 additional reliever puffs of salbutamol/albuterol or', 'levosalbutamol/levalbuterol in a 24 hour period (compared to', 'baseline) on 2 consecutive days;', 'Increase in ICS dose 4 times than the dose at Visit 2;', 'A decrease in AM or PM peak flow of 30% or more on 2', 'consecutive days of treatment, based on the defined stability limit.', 'The Treatment Period stability limit is defined as the respective', 'mean AM or PM peak expiratory flow obtained over the last 7 days', 'prior to randomization (Day1);', 'Severe exacerbation event', 'Two events will be considered as different if the interval between', 'their start dates is equal or greater than 28 days.', 'ASSESSMENT SCHEDULE', 'Screening Period (4 [=1] weeks)', 'Randomized Treatment Period (up to 52 weeks)', 'Post-treatment Period (12 weeks)', 'STATISTICAL CONSIDERATIONS', 'Sample size determination:', 'The sample size of this study was based on a comparison between', 'dupilumab versus placebo with regard to the primary endpoint of annualized', 'rate of severe exacerbations over 52 weeks of treatment for the 3 populations', 'of interest: patients with baseline blood eosinophils >300 cells/L, patients', 'with baseline blood eosinophils >150 cells/L, and patients with type 2', 'inflammatory phenotype (baseline blood eosinophils >150 cells/L or baseline', 'FeNO >20 ppb), with assuming the number of severe exacerbations follows a', 'negative binomial distribution and a randomization ratio of 2:1.', 'Property of the Sanofi Group - strictly confidential', 'Page 14', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}